Company intelligence / Profile preview

Adcendo

Ownership: Private
Development stage: Phase 1

Overview

Currently conducting Phase I Tiffany-01 trial for ADCE-T02 in patients with advanced solid tumors. The trial is ongoing in Australia and will soon begin recruiting in the U.S. ADCE-T02 has shown strong and broad preclinical efficacy and good tolerability.

Therapeutic areas: Oncology
Modalities: Antibody-Drug Conjugates (ADCs)
Industry: Biotech

Drug pipeline

6 assets

ADCE-D01

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Adcendo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adcendo.

Explore the full profile